Ventripoint Diagnostics said this week it won CE Mark approval in the European Union for its VMS+ whole heart analysis system.
The VMS+ system is designed to use conventional 2D ultrasound images to analyze the four chambers of the heart, the Toronto-based company said. Ventripoint touted the system as equivalent in accuracy to magnetic resonance imaging, and said the process to analyze the heart takes only minutes to perform.
“This is great news as it allows the company to bring the capabilities of the VMS+ to cardiologists in Europe and improve cardiac care. The quick acceptance of the VMS+ application is a credit to our development and regulatory groups,” CEO Dr. George Adams said in a press release.
Last August, Ventripoint Diagnostics announced the publication of a study of its VMS heart analysis system, touting that the system’s functionality.